Each tablet contains:
Meloxicam 7.5 or 15 mg
Osteoarthritis, Rheumatoid Arthritis
Dosage and administration:
Initial/Maint: 7.5mg qd
Take with food or just after a meal.
Pregnancy & Breastfeeding:
Category C (<30 weeks gestation) and D (≥30 weeks gestation), not for use in nursing.
ASA or other NSAID allergy that precipitates asthma, urticaria, or allergic-type reactions.
Treatment of perioperative pain in the setting of CABG surgery.
In patients with severe hepatic impairment.
In bleeding disorders.
in patients with renal failure unless receiving dialysis.
Precaution & warnings:
Use lowest effective dose for the shortest duration possible.
May lead to onset of new hypertension, or worsening of preexisting hypertension.
Fluid retention and edema reported. Renal papillary necrosis, renal insufficiency, acute renal failure, and other renal injury reported after long-term use.
Caution in patients with considerable dehydration; rehydrate 1st, then start therapy.
Caution in debilitated patients, with preexisting kidney disease, and asthma.
Avoid with ASA triad/ASA-sensitive asthma. May cause anaphylactoid reactions and serious skin adverse events (eg, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis); discontinue at 1st appearance of rash or other signs of hypersensitivity.
Not a substitute for corticosteroids or for treatment of corticosteroid insufficiency.
May mask signs of inflammation and fever.
Anemia may occur; with long-term use, monitor Hgb/Hct if symptoms of anemia develop.
May inhibit platelet aggregation and prolong bleeding time.
May be associated with a reversible delay in ovulation; not recommended in women with difficulties conceiving, or who are undergoing investigation of infertility.
Abdominal pain, diarrhea, dyspepsia, nausea, headache, anemia, arthralgia, insomnia, URTI, UTI, dizziness, pain, pharyngitis, edema, influenza-like symptoms.
Patients taking ACE inhibitors, thiazides, and loop diuretics (eg, furosemide) may have impaired response to these therapies.
Risk of renal toxicity when coadministered with diuretics, ACE inhibitors, and angiotensin II receptor antagonists.
Increased risk of GI bleeding with anticoagulants (eg, warfarin), smoking, alcohol, and oral corticosteroids.
May diminish antihypertensive effect of ACE inhibitors.
Not recommended with ASA; increased rate of GI ulceration or other complications with low-dose ASA.
May elevate lithium plasma levels; observe for signs of lithium toxicity.
May increase cyclosporine and methotrexate toxicities.
Store below 30°C in a dry place.
Keep out of reach of children.